;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Basal insulin peglispro: Phase III data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Basal insulin peglispro (LY2605541) Business: Endocrine/Metabolic Molecular target: NA Description: Once-daily basal insulin analog Indication: Treat Type I …

    Published on 9/8/2014
  • Basal insulin peglispro: Phase III data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Basal insulin peglispro (LY2605541) Business: Endocrine/Metabolic Molecular target: NA Description: Once-daily basal insulin analog Indication: Treat Type II …

    Published on 9/8/2014
  • Cometriq cabozantinib: Phase III data

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Product: Cometriq cabozantinib (XL184) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2); c-Met …

    Published on 9/8/2014
  • Eravacycline: Interim Phase III data

    Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH), Watertown, Mass. Product: Eravacycline (TP-434) Business: Infectious Molecular target: NA Description: Broad-spectrum fluorocycline antibiotic Indication: Treat complicated…

    Published on 9/8/2014
  • Ferinject ferric carboxymaltose: Phase IV data

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Galenica Ltd. (SIX:GALN), Bern, Switzerland Zeria Pharmaceutical Co. Ltd. (Tokyo:4559), Tokyo, Japan Product: Ferinject ferric carboxymaltose (Injectafer) Business: …

    Published on 9/8/2014
  • Ivabradine: Phase III data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Servier, Neuilly-sur-Seine, France Product: Ivabradine (ONO-1162) (formerly (S-16257)) Business: Cardiovascular Molecular target: Not available Description: …

    Published on 9/8/2014
  • LCZ696: Additional Phase III data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: LCZ696 Business: Cardiovascular Molecular target: Angiotensin II type 1 (AT1) receptor (AGTR1); Neutral endopeptidase (neprilysin) (MME) (NEP) (CD10) …

    Published on 9/8/2014
  • Reslizumab: Phase III data

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Product: Reslizumab (formerly Cinquil) Business: Inflammation Molecular target: Interleukin-5 (IL-5) Description: Humanized mAb against IL-5 …

    Published on 9/8/2014
  • Squalamine eye drops: Clinical trial data

    Ohr Pharmaceutical Inc. (NASDAQ:OHRP), Salt Lake City, Utah Product: Squalamine eye drops (OHR-102) Business: Ophthalmic Molecular target: Calmodulin Description: Topical eye drop formulation of the synthetic small …

    Published on 9/8/2014
  • Tetravalent dengue vaccine: Phase III data

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Tetravalent dengue vaccine Business: Infectious Molecular target: Not available Description: Chimeric tetravalent dengue vaccine consisting of live attenuated …

    Published on 9/8/2014
  • Vatiquinone alpha-tocotrienol quinone: Phase II data

    Edison Pharmaceuticals Inc., Mountain View, Calif. Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Vatiquinone alpha-tocotrienol quinone (EPI-743) Business: Neurology Molecular target: NAD(P)H …

    Published on 9/8/2014
  • Xifaxan rifaximin: Additional Phase III data

    Alfa Wassermann S.p.A., Bologna, Italy Norgine B.V., Amsterdam, the Netherlands Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Product: Xifaxan rifaximin Business: Gastrointestinal Molecular target: Bacterial …

    Published on 9/8/2014
  • Alvocidib: Interim Phase II data

    Tolero Pharmaceuticals Inc., Lehi, Utah Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alvocidib, flavopiridol (formerly HMR 1275) Business: Cancer Molecular target: Cyclin dependent kinase (CDK) Description: …

    Published on 9/1/2014
  • Amigal migalastat: Phase III data

    Amicus Therapeutics Inc. (NASDAQ:FOLD), Cranbury, N.J. Product: Amigal migalastat (AT1001) Business: Endocrine/Metabolic Molecular target: Alpha galactosidase A Description: Small molecule that enhances alpha …

    Published on 9/1/2014
  • Androxal enclomiphene: Phase III data

    Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Androxal enclomiphene Business: Endocrine/Metabolic Molecular target: Androgen receptor; Estrogen receptor Description: Trans-isomer of clomiphene …

    Published on 9/1/2014
  • Auriclosene: Development discontinued

    NovaBay Pharmaceuticals Inc. (NYSE-M:NBY), Emeryville, Calif. Product: Auriclosene (CD07223, NVC-422) Business: Infectious Molecular target: Not available Description: Synthetic analog of the phagocytosis-associated …

    Published on 9/1/2014
  • Autologous T cell therapy against CD19: Updated Phase I/IIa data

    Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Product: Autologous T cell therapy against CD19 (KTE-C19) Business: Cancer Molecular target: CD19 Description: Autologous T cells genetically modified to express a …

    Published on 9/1/2014
  • BAX 855: Phase II/III data

    Nektar Therapeutics (NASDAQ:NKTR), San Francisco, Calif. Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: BAX 855 Business: Hematology Molecular target: Factor VIII Description: Pegylated form of …

    Published on 9/1/2014
  • BL-7010: Phase I/II data

    BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Product: BL-7010 (formerly P(HEMA-co-SS)) Business: Autoimmune Molecular target: NA Description: Non-absorbable gliadin-sequestering polymer Indication: …

    Published on 9/1/2014
  • Ceftazidime/avibactam: Phase III data

    Actavis plc (NYSE:ACT), Dublin, Ireland AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Ceftazidime/avibactam (CAZ AVI, CAZ-104, CAZ104) (formerly NXL104/ceftazidime) Business: Infectious Molecular target: …

    Published on 9/1/2014
  • Ceftolozane/tazobactam: Additional Phase III data

    Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Ceftolozane/tazobactam (formerly CXA-201) Business: Infectious Molecular target: AmpC beta lactamase …

    Published on 9/1/2014
  • Ceftolozane/tazobactam: Additional Phase III data

    Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Ceftolozane/tazobactam (formerly CXA-201) Business: Infectious Molecular target: AmpC beta lactamase …

    Published on 9/1/2014
  • Evolocumab: Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Evolocumab (AMG 145) Business: Endocrine/Metabolic Molecular target: Proprotein convertase subtilisin/kexin type 9…

    Published on 9/1/2014
  • Ixekizumab: Phase III data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Ixekizumab (LY2439821) Business: Autoimmune Molecular target: Interleukin-17A (IL-17A) Description: Humanized mAb against IL-17A Indication: Treat moderate to …

    Published on 9/1/2014
  • ONO-5163: Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Product: ONO-5163, AMG 416 (formerly Velcalcetide, KAI-4169) Business: Endocrine/Metabolic Molecular target: Calcium…

    Published on 9/1/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993